Hormonal
Long-acting GLP-1 receptor agonists significantly reduce glycated hemoglobin (HbA1c) levels and body weight in adults, with greater efficacy observed in patients with type 2 diabetes compared to non-diabetic overweight individuals.
Long-acting GLP-1 receptor agonists (like semaglutide or liraglutide) are effective for lowering blood sugar and reducing body weight in adults. The effect is more pronounced in people with type 2 diabetes. Common side effects include gastrointestinal issues, which may vary by individual. Consult a healthcare provider to determine if these medications are appropriate for your specific health profile.
Long-acting GLP-1 RAs significantly reduced the glycated hemoglobin level and body weight in adults.
Why this rating
Multivariate meta-analysis of 31 double-blind RCTs with 22,948 participants.
Source
Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis
Tzu‐Lin Yeh et al. · PLoS ONE · 2023
DOI 10.1371/journal.pone.0278685
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →